The current challenge of pharmacogenetics is to identify the genetic factors underlying differential drug response.
Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a Model
by Iris Kirstein-Grossman, Jacques S. Beckmann, Doron Lancet and Ariel Miller
The goal of pharmacogenetics is to identify "genetic fingerprints" that may predict a patient's response to pharmaceutical treatment. The use of pharmacogenetics replaces the trial-and-error strategy, which governs much of our clinical decision-making regarding treatment allocation in current medical practice, with individually tailored therapy. We review a pharmacogenetic research model, which implements high-throughput single nucleotide polymorphism technology to establish the correlation between drug-responsiveness and genetic polymorphisms of Copaxone®-treated multiple sclerosis patients. Implementation of similar pharmacogenetic approaches may promote the development of personalized medicine in multiple sclerosis as well as in other diseases. © 2002 Prous Science. All rights reserved.